K Nylén1, M Ost, L Z Csajbok, I Nilsson, K Blennow, B Nellgård, L Rosengren. 1. Department of Neurology, Institute of Clinical Neuroscience, Sahlgrenska University Hospital, University of Göteborg, S-413 45 Göteborg, Sweden. karin.nylen@neuro.gu.se
Abstract
OBJECTIVES: Several studies have established the relevance of S-100 in blood as a marker of brain damage after traumatic brain injury. However, a more specific marker is required and glial fibrillary acidic protein (GFAP) is considered to be a good candidate. METHODS: In order to assess the increase of GFAP in serum (s-GFAP) after a severe traumatic brain injury (TBI) we collected daily serum samples from 59 patients with severe TBI starting on the day of the trauma. S-GFAP was measured using a sandwich ELISA. The Glasgow outcome scale (GOS) assessed outcome after 1 year. RESULTS: All but one patient had maximal s-GFAP values above the laboratory reference value (median increased 10-fold). The highest detected levels were seen during the first days after TBI and then decreased gradually. Patients with unfavourable outcome had significantly (p<0.001) higher maximal s-GFAP values in the acute phase compared with patients with favourable outcome. All patients (n=5) with s-GFAP>15.04 microg /L died (reference level<0.15 microg/L). We found no significant difference in the maximal s-GFAP levels of patients with isolated brain injury in comparison with patients with multiple traumas. CONCLUSION: Serum-GFAP is increased during the first days after a severe traumatic brain injury and related to clinical outcome.
OBJECTIVES: Several studies have established the relevance of S-100 in blood as a marker of brain damage after traumatic brain injury. However, a more specific marker is required and glial fibrillary acidic protein (GFAP) is considered to be a good candidate. METHODS: In order to assess the increase of GFAP in serum (s-GFAP) after a severe traumatic brain injury (TBI) we collected daily serum samples from 59 patients with severe TBI starting on the day of the trauma. S-GFAP was measured using a sandwich ELISA. The Glasgow outcome scale (GOS) assessed outcome after 1 year. RESULTS: All but one patient had maximal s-GFAP values above the laboratory reference value (median increased 10-fold). The highest detected levels were seen during the first days after TBI and then decreased gradually. Patients with unfavourable outcome had significantly (p<0.001) higher maximal s-GFAP values in the acute phase compared with patients with favourable outcome. All patients (n=5) with s-GFAP>15.04 microg /L died (reference level<0.15 microg/L). We found no significant difference in the maximal s-GFAP levels of patients with isolated brain injury in comparison with patients with multiple traumas. CONCLUSION: Serum-GFAP is increased during the first days after a severe traumatic brain injury and related to clinical outcome.
Authors: Linda Papa; Lawrence M Lewis; Jay L Falk; Zhiqun Zhang; Salvatore Silvestri; Philip Giordano; Gretchen M Brophy; Jason A Demery; Neha K Dixit; Ian Ferguson; Ming Cheng Liu; Jixiang Mo; Linnet Akinyi; Kara Schmid; Stefania Mondello; Claudia S Robertson; Frank C Tortella; Ronald L Hayes; Kevin K W Wang Journal: Ann Emerg Med Date: 2011-11-08 Impact factor: 5.721
Authors: Harald Hampel; Yong Shen; Dominic M Walsh; Paul Aisen; Les M Shaw; Henrik Zetterberg; John Q Trojanowski; Kaj Blennow Journal: Exp Neurol Date: 2009-10-06 Impact factor: 5.330
Authors: Andrew Laflam; Brijen Joshi; Kenneth Brady; Gayane Yenokyan; Charles Brown; Allen Everett; Ola Selnes; Edward McFarland; Charles W Hogue Journal: Anesth Analg Date: 2015-01 Impact factor: 5.108
Authors: J Regino Perez-Polo; Harriet C Rea; Kathia M Johnson; Margaret A Parsley; Geda C Unabia; Guojing Xu; Smitha K Infante; Douglas S Dewitt; Claire E Hulsebosch Journal: J Neurotrauma Date: 2013-05-06 Impact factor: 5.269
Authors: Melania M Bembea; William Savage; John J Strouse; Jamie McElrath Schwartz; Ernest Graham; Carol B Thompson; Allen Everett Journal: Pediatr Crit Care Med Date: 2011-09 Impact factor: 3.624
Authors: Keisuke Kawata; Charles Y Liu; Steven F Merkel; Servio H Ramirez; Ryan T Tierney; Dianne Langford Journal: Neurosci Biobehav Rev Date: 2016-05-12 Impact factor: 8.989